BTIG Calls Palvella’s 21% FDA-Driven Drop a Buying Opportunity
The FDA denied Breakthrough Therapy status for QTORIN. BTIG analysts view the decision as a short-term setback and maintain their Buy rating with a $215 price target.
/ 220 items
#andre↓
Agios Ends Tebapivat Program in Sickle Cell Disease, Focuses on Mitapivat
Agios Pharmaceuticals announced it will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile.
Novartis Beats Q2 2026 Expectations as New Drugs Offset Generic Pressure
Novartis reported strong Q2 2026 results with $14.41B sales and a core profit beat, driven by Kisqali (+43%) and Scemblix. Full-year guidance reaffirmed despite Entresto patent cliff.
Morgan Stanley Downgrades Tech Stocks as AI Payoff Doubts Mount
Morgan Stanley downgraded Salesforce, Workday, Intuit, SPS Commerce, Rapid7, PagerDuty, Wix, Vertex, and Nice, citing slow AI revenue growth and legacy business weakness. Price targets cut sharply.
Morgan Stanley Downgrades Adobe to Underweight, Slashes Price Target to $240 Amid AI and Execution Concerns
Morgan Stanley warns about the impact of generative AI, Adobe’s freemium strategy, and ongoing leadership transitions.
Karyopharm Shares Plunge After $3.7M Executive Cash Retention Program
RBC calls the drop overdone and sees it as a buying opportunity.